Department of Medical Pharmacology, Institute of Health Biosciences, The University of Tokushima Graduate School, 1-78-1 Sho-machi, Tokushima 770-8505, Japan.
Nitric Oxide. 2010 Feb 15;22(2):98-103. doi: 10.1016/j.niox.2009.12.002. Epub 2009 Dec 22.
Nitric oxide (NO) has numerous important functions in the kidney, and long-term blockage of nitric oxide synthases in rats by L-NAME results in severe hypertension and progressive kidney damage. On the other hand, NO production seems to be low in patients with chronic kidney disease (CKD), and NO deficiency may play a role in CKD progression. In this review, we summarized the mechanisms of amelioration of renal injury induced by L-NAME treated rats by treatment of nitrite. First, we demonstrate whether orally-administrated nitrite-derived NO can shift to the circulation. When 3mg/kg body weight Na(15)NO(2) was orally administered to rats, an apparent EPR signal derived from Hb(15)NO (A(z)=23.4 gauss) appeared in the blood, indicating that orally ingested nitrite can be a source of NO in vivo. Next, in order to clarify the capacity of nitrite to prevent renal disease, we administered low-dose nitrite (LDN: 0.1mg of sodium nitrite in 1L of drinking water), medium-dose nitrite (MDN: 1mg sodium nitrite/L, which corresponds to the amount of nitrite ingested by vegetarians), or high-dose nitrite (HDN: 10mg sodium nitrite/L) to rats simultaneously with L-NAME (1 g l-NAME/L) for 8 weeks, then examined the blood NO level as a hemoglobin-NO adduct (iron-nitrosyl-hemoglobin) using electron paramagnetic resonance spectroscopy, urinary protein excretion, and renal histological changes at the end of the experiment. It was found that oral administration of MDN and HDN but not LDN increased the blood iron-nitrosyl-hemoglobin concentration to the normal level, ameliorated the L-NAME-induced proteinuria, and reduced renal histological damage. The findings demonstrate that chronic administration of a mid-level dietary dose of nitrite restores the circulating iron-nitrosyl-hemoglobin levels reduced by L-NAME and that maintenance of the circulating iron-nitrosyl-hemoglobin level in a controlled range protects against L-NAME-induced renal injury. Taking these findings together, we propose that dietary supplementation of nitrite is a potentially useful nonpharmacological strategy for maintaining circulating NO level in order to prevent or slow the progression of renal disease. It had been believed that nitrite could result in intragastric formation of nitrosamines, which had been linked to esophageal and other gastrointestinal cancers. However, there is no positive association between the intake of nitrate or nitrite and gastric and pancreatic cancer by recent researches. Furthermore, nitrate-derived NO formation pathway is a possible mechanism for the hypotensive effect of vegetable- and fruit-rich diets, which may explain, at least in part, the mechanism of the Dietary Approach to Stop Hypertension (DASH) diet-induced hypotensive and organ-protective effects. Further research is needed to investigate the interaction between nitrite-nitrate intakes and human health.
一氧化氮(NO)在肾脏中具有许多重要功能,长期阻断大鼠的一氧化氮合酶会导致严重的高血压和进行性肾脏损伤。另一方面,慢性肾脏病(CKD)患者的 NO 产生似乎较低,NO 缺乏可能在 CKD 进展中发挥作用。在这篇综述中,我们总结了用亚硝酸盐治疗 L-NAME 处理大鼠引起的肾损伤的机制。首先,我们证明口服亚硝酸盐衍生的 NO 是否可以转移到循环中。当给大鼠口服 3mg/kg 体重的 Na(15)NO(2)时,血液中出现明显的源自 Hb(15)NO 的 EPR 信号(A(z)=23.4高斯),表明口服亚硝酸盐可以成为体内 NO 的来源。接下来,为了阐明亚硝酸盐预防肾脏疾病的能力,我们同时给予低剂量亚硝酸盐(LDN:1L 饮用水中 0.1mg 亚硝酸钠)、中剂量亚硝酸盐(MDN:1mg 亚硝酸钠/L,相当于素食者摄入的亚硝酸盐量)或高剂量亚硝酸盐(HDN:10mg 亚硝酸钠/L)L-NAME(1g l-NAME/L)8 周,然后使用电子顺磁共振光谱法检查血液中作为血红蛋白-NO 加合物(铁-亚硝酰血红蛋白)的血液 NO 水平、尿蛋白排泄和实验结束时的肾脏组织学变化。结果发现,口服 MDN 和 HDN 而非 LDN 增加了血液中铁-亚硝酰血红蛋白的浓度至正常水平,改善了 L-NAME 引起的蛋白尿,并减少了肾脏组织学损伤。这些发现表明,慢性给予中等水平的饮食剂量的亚硝酸盐可恢复 L-NAME 降低的循环铁-亚硝酰血红蛋白水平,并且将循环铁-亚硝酰血红蛋白水平维持在可控范围内可防止 L-NAME 引起的肾脏损伤。综合这些发现,我们提出饮食补充亚硝酸盐可能是一种有用的非药物策略,用于维持循环 NO 水平以预防或减缓肾脏疾病的进展。人们曾认为,亚硝酸盐会在胃内形成亚硝胺,这与食管癌和其他胃肠道癌症有关。然而,最近的研究并没有发现硝酸盐或亚硝酸盐的摄入与胃癌和胰腺癌之间存在正相关关系。此外,硝酸盐衍生的 NO 形成途径可能是富含蔬菜和水果的饮食降压作用的机制之一,这至少可以部分解释饮食控制高血压(DASH)饮食引起的降压和器官保护作用的机制。需要进一步研究来研究亚硝酸盐-硝酸盐摄入量与人类健康之间的相互作用。